The common mineral deficiency that can cause heart palpitations - are you at risk?
POTASSIUM deficiency can be dangerous to treat with supplements, meaning that in order to treat the symptoms of deficiency you'll have to look at changing your diet. (Source: Daily Express - Health)
Source: Daily Express - Health - December 3, 2021 Category: Consumer Health News Source Type: news

Lower Urinary Sodium, Higher Potassium Tied to Lower CV Risk Lower Urinary Sodium, Higher Potassium Tied to Lower CV Risk
A new observational study using direct urinary measurement, along with previous randomized data, provides support for public health advice to reduce sodium and increase potassium intake prevent CVD.Medscape Medical News (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - November 17, 2021 Category: Primary Care Tags: Cardiology News Source Type: news

Less Salt, More Potassium for a Healthier Heart: Study
Title: Less Salt, More Potassium for a Healthier Heart: StudyCategory: Health NewsCreated: 11/15/2021 12:00:00 AMLast Editorial Review: 11/15/2021 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - November 15, 2021 Category: Cardiology Source Type: news

Vonoprazan Beats PPIs in H pylori Eradication Vonoprazan Beats PPIs in H pylori Eradication
The oral potassium-competitive acid blocker was especially better against clarithromycin-resistant strains.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - November 3, 2021 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

What is Refeeding Syndrome?
Discussion Anorexia nervosa is an eating disorder with an intense fear of being overweight (i.e. distorted body image), and self-starvation and excessive weight loss. It is more common in women (1.2%) than men (0.2%) but can be seen in both genders. Risk factors include high-intelligence, perfectionism/inflexibility, anxiety, activities where thinner body types are expected (e.g. dancer, diver, gymnast, long-distance runner, volleyball player, etc.) Other eating disorders include bulimia nervosa (i.e. cycles of binge eating and then purging), binge eating disorder (i.e. purging), orthorexia (i.e. obsessions with healthful ...
Source: PediatricEducation.org - October 25, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Accidental ocular injury by topical dermatological agent: potassium permanganate (KMnO4) - Kandpal R, Gautam S.
Potassium permanganate (KMnO4) is a commonly used topical therapeutic agent in dermatology. It is readily available and widely used as a disinfectant and astringent. Due to its antiseptic and astringent properties, it is used for acute and sub-acute eczema... (Source: SafetyLit)
Source: SafetyLit - October 22, 2021 Category: International Medicine & Public Health Tags: Burns, Electricity, Explosions, Fire, Scalds Source Type: news

Mars Was Always Destined to Die
Mars is the solar system’s near-miss world. Earth may have gotten everything right when it came to sustaining life—atmosphere, water, proximity to the sun. Mercury, Venus and the outer planets, with their extreme temperatures and inhospitable chemistry, may have gotten everything wrong. Mars, on the other hand, came so close, yet fell short. Thanks to data from rovers and other spacecraft, we know that the Red Planet once fairly sloshed with water—with dry deltas, riverbeds, and sea basins stamped into its surface. But 4 billion years ago, the Martian core cooled, shutting down the dynamo that sustained i...
Source: TIME: Science - September 21, 2021 Category: Science Authors: Jeffrey Kluger Tags: Uncategorized healthscienceclimate Space Source Type: news

New Data on RYBREVANT ® (amivantamab-vmjw) in Combination with Lazertinib Show Early Activity in Patients with Non-Small Cell Lung Cancer Whose Disease Has Progressed After Both Osimertinib and Platinum-Based Chemotherapy
September 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced preliminary results from the Phase 1b CHRYSALIS-2 (NCT04077463) study evaluating RYBREVANT® (amivantamab-vmjw) in combination with lazertinib in the treatment of patients with non-small cell lung cancer (NSCLC) characterized by epidermal growth factor receptor (EGFR) exon 19 deletion or L858R mutations whose disease had progressed after treatment with osimertinib and platinum chemotherapy.[i] While previously reported results have demonstrated durable responses with RYBREVANT® in combination with lazertini...
Source: Johnson and Johnson - September 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

RYBREVANT ® (amivantamab-vmjw) Provides Higher Activity and Longer Duration of Response When Used in Combination with Lazertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer Who Have Failed Osimertinib
September 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced a new analysis from the CHRYSALIS (NCT02609776) study evaluating RYBREVANT® (amivantamab-vmjw) monotherapy and a combination regimen with lazertinib in advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations who progressed after osimertinib.[1] The analysis showed higher activity and longer duration of response (DOR) in patients treated with the combination therapy, demonstrating the potential benefit of targeting the extracellular (outer) and catalytic (i...
Source: Johnson and Johnson - September 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Announces U.S. FDA Approval of INVEGA HAFYERA ™(6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia
TITUSVILLE, N.J., Sept. 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic INVEGA HAFYERA™ (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults. Before transitioning to INVEGA HAFYERA™, patients must be adequately treated with INVEGA SUSTENNA® (1-month paliperidone palmitate) for at least four months, or INVEGA TRINZA® (3-month paliperidone palmitate) for at least one 3-month injection cycle.1 The FDA approval of INVEGA ...
Source: Johnson and Johnson - September 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Micro-K (Potassium Chloride Extended-Release) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 1, 2021 Category: Drugs & Pharmacology Source Type: news

Tegoprazan vs. Placebo in Non-erosive Reflux Disease Tegoprazan vs. Placebo in Non-erosive Reflux Disease
Is tegoprazan, a novel, long-acting potassium-competitive acid blocker, superior to placebo in patients with non-erosive reflux disease?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 30, 2021 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

High blood pressure: The surprising food type rich in potassium to lower your readings
HIGH blood pressure, or hypertension as its often referred to, is a serious condition affecting millions worldwide. Diet is key when it comes to healthy readings with sodium or salt being the biggest precursor to increasing hypertension risk. A certain food type, however, has been shown to counteract sodium in the body which in turn lowers your readings. (Source: Daily Express - Health)
Source: Daily Express - Health - August 28, 2021 Category: Consumer Health News Source Type: news

Janssen Presents Phase 1 Results for RYBREVANTTM (amivantamab-vmjw) in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutations
August 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced preliminary data from the Phase 1 CHRYSALIS study evaluating RYBREVANTTM (amivantamab-vmjw) for the treatment of patients with non-small cell lung cancer (NSCLC) with mesenchymal-epithelial transition (MET) exon 14 skipping (METex14) mutations. The initial data showed anti-tumor activity in patients with METex14 mutations and a safety profile consistent with reported experience at the approved CHRYSALIS Phase 2 dose (RYBREVANTTM 1050 mg [<80 kg] / 1400 mg [≥80 kg]).[1] These findings will be featured at th...
Source: Johnson and Johnson - August 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news